DOSE ESCALATION OF NEXT GENERATION ANTI-CTLA-4 ANTIBODY ONC-392 IN COMBINATION WITH FIXED DOSE OF PEMBROLIZUMAB IN PATIENTS WITH ADVANCED SOLID TUMORS

被引：0
|
作者：
Hu-Lieskovan, Siwen [1 ]
He, Kai [2 ]
Tang, Mei [3 ]
Chen, Dan [4 ]
Liu, Yang [4 ]
Zheng, Pan [4 ]
Li, Tianhong [5 ]
机构：
[1] Univ Utah, Huntsman Canc Inst, Salt Lake City, UT USA
[2] Ohio State Univ, Canc Ctr, Columbus, OH 43210 USA
[3] Greater Baltimore Med Ctr, Baltimore, MD USA
[4] OncoC4 Inc, Rockville, MD USA
[5] Univ Calif Davis, Sacramento, CA 95817 USA
来源：
JOURNAL FOR IMMUNOTHERAPY OF CANCER | 2022年 / 10卷
关键词：
D O I：
10.1136/jitc-2022-SITC2022.0594
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
594
引用
收藏
页码：A622 / A622
页数：1
相关论文
共 50 条
  • [41] Phase I dose-escalation study of cabazitaxel administered in combination with cisplatin in patients with advanced solid tumors
    Lockhart, A. Craig
    Sundaram, Shankar
    Sarantopoulos, John
    Mita, Monica M.
    Wang-Gillam, Andrea
    Moseley, Jennifer L.
    Barber, Stephanie L.
    Lane, Alex R.
    Wack, Claudine
    Kassalow, Laurent
    Dedieu, Jean-Francois
    Mita, Alain C.
    INVESTIGATIONAL NEW DRUGS, 2014, 32 (06) : 1236 - 1245
  • [42] Phase I Dose-Escalation Study of Intravenous Aflibercept in Combination with Docetaxel in Patients with Advanced Solid Tumors
    Isambert, Nicolas
    Freyer, Gilles
    Zanetta, Sylvie
    You, Benoit
    Fumoleau, Pierre
    Falandry, Claire
    Favier, Laure
    Assadourian, Sylvie
    Soussan-Lazard, Karen
    Ziti-Ljajic, Samira
    Trillet-Lenoir, Veronique
    CLINICAL CANCER RESEARCH, 2012, 18 (06) : 1743 - 1750
  • [43] A phase I dose-escalation and pharmacokinetic study of sunitinib in combination with docetaxel in patients with advanced solid tumors
    Robert, F.
    Sandler, A.
    Schiller, J. H.
    Ilagan, J.
    Harper, K.
    Vermeulen, W.
    Liu, G.
    Tye, L.
    Chao, R.
    Verkh, L.
    Traynor, A.
    MOLECULAR CANCER THERAPEUTICS, 2007, 6 (12) : 3514S - 3515S
  • [44] A phase I dose-escalation study of selumetinib in combination with docetaxel or dacarbazine in patients with advanced solid tumors
    Patricia M. LoRusso
    Jeffrey R. Infante
    Kevin B. Kim
    Howard A. Burris
    Gregory Curt
    Ugochi Emeribe
    Delyth Clemett
    Helen K. Tomkinson
    Roger B. Cohen
    BMC Cancer, 17
  • [45] A phase I dose-escalation study of Selumetinib in combination with Erlotinib or Temsirolimus in patients with advanced solid tumors
    Infante, Jeffrey R.
    Cohen, Roger B.
    Kim, Kevin B.
    Burris, Howard A., III
    Curt, Gregory
    Emeribe, Ugochi
    Clemett, Delyth
    Tomkinson, Helen K.
    LoRusso, Patricia M.
    INVESTIGATIONAL NEW DRUGS, 2017, 35 (05) : 576 - 588
  • [46] A phase I dose-escalation study of selumetinib in combination with docetaxel or dacarbazine in patients with advanced solid tumors
    LoRusso, Patricia M.
    Infante, Jeffrey R.
    Kim, Kevin B.
    Burris, Howard A., III
    Curt, Gregory
    Emeribe, Ugochi
    Clemett, Delyth
    Tomkinson, Helen K.
    Cohen, Roger B.
    BMC CANCER, 2017, 17
  • [47] A phase 1 dose-escalation study to investigate the safety, efficacy, pharmacokinetics, and pharmacodynamic activity of CLN-619 (anti-MICA/MICB antibody) alone and in combination with pembrolizumab in patients with advanced solid tumors
    Powderly, John D.
    Gutierrez, Martin
    Wang, Judy S.
    Hamilton, Erika P.
    Sharma, Manish
    Spira, Alexander I.
    Millward, Michael
    Shackleton, Mark J.
    Frentzas, Sophia
    Koczywas, Marianna
    Mehta, Naveen
    Christensen, Ann Marie
    Shapiro, Irina
    Whalen, Kerry
    Michaelson, Jennifer
    Baeuerle, Patrick
    Janik, John Edward
    Rasco, Drew W.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [48] A phase 1 dose-escalation study to investigate the safety, efficacy, pharmacokinetics, and pharmacodynamic activity of cln-619 (Anti-MICA/B antibody) alone and in combination with pembrolizumab in patients with advanced solid tumors
    Wang, Judy S.
    Gutierrez, Martin
    Rasco, Drew W.
    Melero Bermejo, Ignacio
    Powderly, John D.
    Hamilton, Erika P.
    Millward, Michael
    Maria Arance, Ana
    Stec, Rafal
    Moreno, Victor
    Sharma, Manish
    Lugowska, Iwona A.
    Shackleton, Mark J.
    Frentzas, Sophia
    Edward Janik, John
    Liu, Tracy
    Shapiro, Irina
    Whalen, Kerry
    Alan Jones, Jeffrey
    Spira, Alexander I.
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [49] AGEN1181, AN FC-ENHANCED ANTI-CTLA-4 ANTIBODY, ALONE AND IN COMBINATION WITH BALSTILIMAB (ANTI-PD-1) IN PATIENTS WITH ADVANCED SOLID TUMORS: INITIAL PHASE I RESULTS
    El-Khoueiry, Anthony
    Bullock, Andrea
    Tsimberidou, Apostolia
    Mahadevan, Daruka
    Wilky, Breelyn
    Twardowski, Przemyslaw
    Bockorny, Bruno
    Moser, Justin
    Feliu, Waldo Ortuzar
    Grossman, Joseph
    Rosenthal, Katherine
    O'Day, Steven
    Gordon, Michael
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2021, 9 : A509 - A509
  • [50] Phase 1 study of BA3071, an anti-CTLA-4 conditionally active biologic, in combination with nivolumab in advanced solid tumors
    Thomas, Jacob Stephen
    Selfridge, Jennifer Eva
    Albany, Costantine
    Taylor, Matthew H.
    Mehmi, Inderjit
    Kwatra, Vineet
    Hu-Lieskovan, Siwen
    de Souza, Paul L.
    Llorin-Sangalang, Judith Dubal
    Aysola, Kartik
    Hamid, Omid
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
12345